S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

NTLA Intellia Therapeutics Inc

21.2175

0.2375 (1.13%)

Last Updated: 01:15:33

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Intellia Therapeutics Charts.

Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Intellia Therapeutics Charts.

Intellia Therapeutics, Inc. News

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
Thursday 10 October 2024 (1 week ago) • GlobeNewswire Inc.

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Monday 7 October 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Friday 4 October 2024 (2 weeks ago) • GlobeNewswire Inc.

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
Tuesday 1 October 2024 (2 weeks ago) • GlobeNewswire Inc.

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
Thursday 12 September 2024 (1 month ago) • GlobeNewswire Inc.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Wednesday 4 September 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 9 August 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 8 August 2024 (2 months ago) • Edgar (US Regulatory)

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Thursday 8 August 2024 (2 months ago) • GlobeNewswire Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
Thursday 1 August 2024 (3 months ago) • GlobeNewswire Inc.

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
Tuesday 30 July 2024 (3 months ago) • GlobeNewswire Inc.

More Intellia Therapeutics, Inc. News Articles

Sterling vs AUD

Woodside Petroleum

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions